Related Experiment Video
Updated: Jul 22, 2026

Screening Assay for Oxidative Stress in a Feline Astrocyte Cell Line, G355-5
Published on: July 13, 2011
Antioxidant therapy in neurologic disease
1Department of Clinical Neurological Sciences, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland. normandelanty@eircom.net
Abstract:
Free radical or oxidative injury may be a fundamental mechanism underlying a number of human neurologic diseases. Therapy using free radical scavengers (antioxidants) has the potential to prevent, delay, or ameliorate many neurologic disorders. However, the biochemistry of oxidative pathobiology is complex, and optimum antioxidant therapeutic options may vary and need to be tailored to individual diseases. In vitro and animal model studies support the potential beneficial role of various antioxidant compounds in neurologic disease. However, the results of clinical trials using various antioxidants, including vitamin E, tirilazad, N-acetylcysteine, and ebselen, have been mixed. Potential reasons for these mixed results include lack of pretrial dose-finding studies and failure to appreciate and characterize the individual unique oxidative processes occurring in different diseases. Moreover, therapy with antioxidants may need to be given early in chronic insidious neurologic disorders to achieve an appreciable clinical benefit. Predisease screening and intervention in at-risk individuals may also need to be considered in the near future.
Insights
Oxidative injury is key in neurologic diseases. Antioxidant therapies show promise but require disease-specific approaches and early intervention for effectiveness in neurological disorders.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Oxidative stress and free radical damage are implicated in the pathogenesis of numerous human neurologic diseases.
- Antioxidant (free radical scavenger) therapy offers a potential strategy for preventing, delaying, or mitigating these neurological disorders.
- The complex biochemistry of oxidative pathobiology necessitates tailored antioxidant approaches for individual diseases.
Purpose of the Study:
- To explore the potential role of antioxidant compounds in managing neurologic diseases.
- To investigate the reasons behind mixed results in clinical trials of antioxidant therapies for neurological conditions.
- To emphasize the need for disease-specific and timely antioxidant interventions.
Main Methods:
- Review of in vitro and animal model studies on antioxidant compounds in neurologic disease.
- Analysis of clinical trial outcomes for various antioxidants (e.g., vitamin E, N-acetylcysteine).
- Examination of factors influencing antioxidant therapy efficacy, including dosage and disease-specific oxidative processes.
Main Results:
- In vitro and animal studies suggest potential benefits of antioxidants in neurologic diseases.
- Clinical trial results for antioxidants like vitamin E, tirilazad, N-acetylcysteine, and ebselen have been inconsistent.
- Mixed outcomes may stem from inadequate dose-finding studies and a failure to characterize unique disease-specific oxidative mechanisms.
Conclusions:
- Optimizing antioxidant therapy for neurologic diseases requires understanding and addressing individual disease biochemistry.
- Early intervention with antioxidants in chronic neurologic disorders is crucial for achieving clinical benefits.
- Future strategies may involve pre-disease screening and intervention in at-risk populations for neurodegenerative diseases.
More Related Videos
08:16Method for the Assessment of Effects of a Range of Wavelengths and Intensities of Red/near-infrared Light Therapy on Oxidative Stress In Vitro
Published on: March 21, 2015
10:13Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
Published on: July 31, 2017
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Drug Therapy
Antianxiety Medications